Trials / Terminated
TerminatedNCT02739360
Roll Over Study to Provide Idelalisib to Participants Previously Treated With the Investigational PI3Kδ Inhibitor, GS-9820
An Open Label, Roll Over Study to Provide Idelalisib to Subjects Previously Treated With the Investigational PI3Kδ Inhibitor, GS-9820
- Status
- Terminated
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 3 (actual)
- Sponsor
- Gilead Sciences · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this study is to provide idelalisib to participants receiving GS-9820 in Gilead-sponsored Study GS-US-315-0102 at the time of study closure.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Idelalisib | Idelalisib 150 mg tablet administered orally twice daily |
Timeline
- Start date
- 2016-05-04
- Primary completion
- 2017-12-28
- Completion
- 2017-12-28
- First posted
- 2016-04-15
- Last updated
- 2020-03-04
- Results posted
- 2019-01-16
Locations
1 site across 1 country: Netherlands
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT02739360. Inclusion in this directory is not an endorsement.